Allarity Therapeutics, Inc.

Develops personalized cancer drugs using a diagnostic platform to predict patient response.

ALLR | NDAQ

Overview

Corporate Details

ISIN(s):: US0167445008
LEI:
Country:: United States of America
Address:: 24 SCHOOL ST., 2ND FLOOR, 2108 BOSTON
Website:: https://allarity.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing personalized cancer treatments. The company leverages its proprietary Drug Response Predictor (DRP®) technology, a diagnostic platform that analyzes tumor biology to predict a patient's response to specific therapies. This approach aims to refine patient selection and improve clinical outcomes for its pipeline of in-licensed oncology therapeutics. Allarity's lead clinical program is stenoparib, an orally available, dual-action small molecule inhibitor being advanced for patients with advanced recurrent ovarian cancer. The company's mission is to enhance patient outcomes through data-driven decision-making and personalized cancer care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allarity Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allarity Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allarity Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
GALECTIN THERAPEUTICS INC Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.	United States of America	GALT
Galecto, Inc. Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.	United States of America	GLTO
Galmed Pharmaceuticals Ltd. Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.	United States of America	GLMD
GC CELL CORPORATION Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.	South Korea	144510
Gelteq Ltd Ingestible gel platform for enhanced oral delivery of drugs & nutrients for human & animal health.	United States of America	GELS
GemVax & KAEL Co.,Ltd. Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.	South Korea	082270
Gencurix Inc. Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.	South Korea	229000
GENELUX Corp Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.	United States of America	GNLX
GENEMATRIX INC. Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.	South Korea	109820
Genenta Science S.p.A. Develops cell & gene therapies using engineered stem cells to treat solid tumors.	United States of America	GNTA